Cardiff Oncology shares plunge after Q2 earnings miss
Redhill Biopharma Ltd . (NASDAQ:RDHL) shares have tumbled to a 52-week low, touching the $3 mark as the company grapples with a challenging year. According to InvestingPro data, the stock’s RSI indicates oversold territory, while the company’s financial health score stands at a concerning 1.34, labeled as "WEAK." The pharmaceutical firm, which specializes in developing treatments for inflammatory and gastrointestinal diseases, has seen its stock price plummet by 78% over the past year. Investors have been cautious, reflecting concerns over the company’s pipeline progress and market conditions that have broadly impacted the biotech sector. The significant drop to this year’s low underscores the volatility and the hurdles Redhill faces as it strives to recover and reassure its stakeholders. With a current market cap of just $3.87 million and rapidly depleting cash reserves, the company faces significant challenges ahead. InvestingPro subscribers can access 15+ additional key insights about RDHL’s financial position and future prospects.
In other recent news, RedHill Biopharma Ltd. reported a decrease in net revenues for Q1 2022, dropping to $18.2 million from $22.1 million in the previous quarter. Despite this decline, the company maintained a gross profit of $10.2 million, reflecting a robust gross margin of 56%. RedHill has been focusing on cost efficiency, significantly reducing its R&D expenses from $5.9 million to $3.1 million and cutting operating cash use by over 70% to approximately $4 million. Additionally, Hyloris Pharmaceuticals SA has entered into a licensing agreement with RedHill for the global development and commercialization of RHB-102, excluding North America, which could potentially bring up to $60 million in milestone payments to RedHill.
The collaboration is set to leverage the promising results from RHB-102’s Phase 2 and Phase 3 studies in the United States. The antiemetic drug is in advanced development stages for various indications, including acute gastroenteritis and IBS-D. Meanwhile, RedHill is targeting positive cash flow from operations in the second half of 2022 and has plans to save $50 million over 18 months through a comprehensive cost reduction strategy. The company is also exploring potential acquisitions of revenue-generating products and seeking external funding for its R&D programs. These strategic moves highlight RedHill’s efforts to navigate ongoing challenges in the biotech sector while aiming for financial stability and growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.